Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 1950 | 7.235 |
09:36 ET | 100 | 7.22 |
09:38 ET | 1000 | 7.24 |
09:39 ET | 530 | 7.3 |
09:41 ET | 4368 | 7.2963 |
09:43 ET | 1989 | 7.29 |
09:45 ET | 185 | 7.32 |
09:48 ET | 6072 | 7.33 |
09:50 ET | 3827 | 7.2052 |
09:52 ET | 948 | 7.31 |
09:54 ET | 200 | 7.31 |
09:56 ET | 300 | 7.22 |
09:59 ET | 2580 | 7.2685 |
10:01 ET | 200 | 7.285 |
10:08 ET | 200 | 7.295 |
10:10 ET | 932 | 7.3 |
10:12 ET | 3000 | 7.3043 |
10:14 ET | 350 | 7.2883 |
10:15 ET | 604 | 7.22 |
10:17 ET | 258 | 7.2892 |
10:19 ET | 1100 | 7.2007 |
10:21 ET | 5723 | 7.14 |
10:24 ET | 507 | 7.0608 |
10:26 ET | 600 | 7.1 |
10:28 ET | 1100 | 7.06 |
10:30 ET | 208 | 7.1 |
10:32 ET | 645 | 7.065 |
10:33 ET | 1400 | 7.015 |
10:35 ET | 100 | 7.04 |
10:39 ET | 1800 | 7.08 |
10:42 ET | 335 | 7.1092 |
10:44 ET | 400 | 7.1 |
10:46 ET | 4232 | 7.1188 |
10:50 ET | 6300 | 7.07 |
10:51 ET | 2755 | 7.11 |
11:00 ET | 3343 | 7.07 |
11:02 ET | 536 | 7.05 |
11:04 ET | 800 | 7.085 |
11:06 ET | 100 | 7.05 |
11:08 ET | 589 | 7.05 |
11:09 ET | 2772 | 7.07 |
11:11 ET | 483 | 7.05 |
11:13 ET | 10255 | 7.06 |
11:15 ET | 1500 | 7.09 |
11:18 ET | 786 | 7.05 |
11:20 ET | 200 | 7.02 |
11:22 ET | 5825 | 7.13 |
11:27 ET | 200 | 7.125 |
11:29 ET | 100 | 7.125 |
11:33 ET | 1375 | 7.11 |
11:38 ET | 100 | 7.07 |
11:42 ET | 2500 | 7.0519 |
11:45 ET | 1433 | 7.05 |
11:47 ET | 100 | 7.02 |
11:54 ET | 352 | 7.05 |
11:56 ET | 130 | 7.05 |
11:58 ET | 100 | 7.03 |
12:00 ET | 3206 | 7.0312 |
12:02 ET | 138 | 7.04 |
12:07 ET | 100 | 7.05 |
12:09 ET | 8089 | 6.96 |
12:12 ET | 2702 | 7.02 |
12:18 ET | 300 | 7 |
12:20 ET | 100 | 7 |
12:34 ET | 614 | 7 |
12:38 ET | 100 | 6.98 |
12:41 ET | 100 | 6.97 |
12:45 ET | 3225 | 7.025 |
12:48 ET | 516 | 7.05 |
12:50 ET | 200 | 7.02 |
01:03 ET | 100 | 6.98 |
01:10 ET | 3692 | 6.98 |
01:12 ET | 2625 | 7.01 |
01:14 ET | 1100 | 6.98 |
01:15 ET | 1000 | 7.0172 |
01:21 ET | 200 | 6.96 |
01:24 ET | 1000 | 6.9957 |
01:28 ET | 600 | 7.01 |
01:30 ET | 5307 | 6.95 |
01:32 ET | 603 | 6.9 |
01:33 ET | 223 | 6.919 |
01:35 ET | 195 | 6.9 |
01:37 ET | 8417 | 6.91 |
01:39 ET | 500 | 6.93 |
01:42 ET | 300 | 6.91 |
01:48 ET | 600 | 6.93 |
01:51 ET | 195 | 6.9273 |
01:53 ET | 674 | 6.939 |
01:57 ET | 100 | 6.97 |
02:02 ET | 1212 | 6.9899 |
02:08 ET | 100 | 6.9782 |
02:18 ET | 400 | 6.945 |
02:24 ET | 2007 | 6.89 |
02:26 ET | 300 | 6.915 |
02:27 ET | 2205 | 6.88 |
02:29 ET | 800 | 6.87 |
02:36 ET | 583 | 6.91 |
02:40 ET | 200 | 6.91 |
02:44 ET | 800 | 6.99 |
02:45 ET | 300 | 6.986 |
03:02 ET | 807 | 6.96 |
03:03 ET | 1295 | 6.8888 |
03:05 ET | 10079 | 6.92 |
03:07 ET | 13299 | 6.76 |
03:09 ET | 100 | 6.8 |
03:12 ET | 8135 | 6.85 |
03:16 ET | 300 | 6.86 |
03:18 ET | 703 | 6.825 |
03:20 ET | 200 | 6.865 |
03:21 ET | 2089 | 6.855 |
03:23 ET | 6995 | 6.855 |
03:25 ET | 2900 | 6.83 |
03:27 ET | 146 | 6.8693 |
03:30 ET | 1542 | 6.85 |
03:32 ET | 624 | 6.8895 |
03:34 ET | 1166 | 6.91 |
03:36 ET | 917 | 6.89 |
03:38 ET | 2174 | 6.89 |
03:39 ET | 500 | 6.865 |
03:41 ET | 1642 | 6.87 |
03:43 ET | 4379 | 6.88 |
03:45 ET | 1359 | 6.89 |
03:50 ET | 1193 | 6.85 |
03:52 ET | 3447 | 6.9 |
03:54 ET | 1684 | 6.91 |
03:56 ET | 100 | 6.9174 |
03:57 ET | 2437 | 6.92 |
03:59 ET | 14389 | 6.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 208.6M | -4.1x | --- |
Gossamer Bio Inc | 208.4M | -2.4x | --- |
XBiotech Inc | 215.1M | -6.7x | --- |
Cabaletta Bio Inc | 200.8M | -2.5x | --- |
ATAI Life Sciences NV | 217.6M | -3.0x | --- |
Pyxis Oncology Inc | 222.8M | -2.9x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $222.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.